Pharmacogenetic in the Therapeutic Strategy in Depressed Elderly
Pharmacogenetic in the Therapeutic Strategy in Depressed Elderly
The study aims to assess the therapeutic benefits of the adaptation of the antidepressant dose to the metabolic capacity (cytochrome P450 2D6) of elderly depressed patients.
Therapeutic benefits are evaluated through the enhancement of efficiency, decrease of the action time and the after effects.
Inclusion Criteria:
Exclusion Criteria: